kr
52.90
Sep 26
Business Description
Aker BioMarine ASA
ISIN : NO0010886625
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.09 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.51 | |||||
Debt-to-EBITDA | 3.22 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 0.97 | |||||
Beneish M-Score | -3.29 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.8 | |||||
3-Year EBITDA Growth Rate | -7.5 | |||||
3-Year EPS without NRI Growth Rate | -27 | |||||
3-Year FCF Growth Rate | 69.8 | |||||
3-Year Book Growth Rate | 5.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -12.73 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 4.32 | |||||
9-Day RSI | 7.64 | |||||
14-Day RSI | 12.71 | |||||
6-1 Month Momentum % | 49.41 | |||||
12-1 Month Momentum % | 121.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.97 | |||||
Quick Ratio | 1.58 | |||||
Cash Ratio | 0.06 | |||||
Days Inventory | 305.11 | |||||
Days Sales Outstanding | 84.52 | |||||
Days Payable | 70.07 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 8.82 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 33.1 | |||||
Operating Margin % | -0.08 | |||||
Net Margin % | -0.08 | |||||
FCF Margin % | 8.5 | |||||
ROE % | -0.07 | |||||
ROA % | -0.03 | |||||
3-Year ROIIC % | 14.6 | |||||
ROC (Joel Greenblatt) % | -0.41 | |||||
ROCE % | -0.32 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 54.28 | |||||
Forward PE Ratio | 21.31 | |||||
PE Ratio without NRI | 98.28 | |||||
Price-to-Owner-Earnings | 14.43 | |||||
PEG Ratio | 9.36 | |||||
PS Ratio | 1.52 | |||||
PB Ratio | 1.19 | |||||
Price-to-Tangible-Book | 1.97 | |||||
Price-to-Free-Cash-Flow | 23.27 | |||||
Price-to-Operating-Cash-Flow | 7.83 | |||||
EV-to-EBIT | -265.67 | |||||
EV-to-Forward-EBIT | 16.49 | |||||
EV-to-EBITDA | 10.07 | |||||
EV-to-Forward-EBITDA | 10.03 | |||||
EV-to-Revenue | 1.86 | |||||
EV-to-Forward-Revenue | 2.17 | |||||
EV-to-FCF | 22.67 | |||||
Price-to-Projected-FCF | 529 | |||||
Price-to-Graham-Number | 2.93 | |||||
Price-to-Net-Current-Asset-Value | 3.94 | |||||
Earnings Yield (Greenblatt) % | -0.38 | |||||
FCF Yield % | 6.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Aker BioMarine ASA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 3,242.307 | ||
EPS (TTM) (kr) | 0.947 | ||
Beta | 0 | ||
Volatility % | 54.39 | ||
14-Day RSI | 12.71 | ||
14-Day ATR (kr) | 3.027083 | ||
20-Day SMA (kr) | 87.995 | ||
12-1 Month Momentum % | 121.83 | ||
52-Week Range (kr) | 45.8 - 104 | ||
Shares Outstanding (Mil) | 87.69 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aker BioMarine ASA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Aker BioMarine ASA Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Aker BioMarine ASA Frequently Asked Questions
What is Aker BioMarine ASA(OSTO:AKBMo)'s stock price today?
When is next earnings date of Aker BioMarine ASA(OSTO:AKBMo)?
Does Aker BioMarine ASA(OSTO:AKBMo) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |